Is a matched unrelated donor search needed for all allogeneic transplant candidates?

Donor availability for allogeneic transplantation remains an important factor in determining outcomes of a successful transplant. We examined outcomes of 242 patients treated over 3 years who had a matched unrelated donor (MUD) search at our institution. One hundred sixty patients (66%) had a 10 of 10 MUD identified, and 85 (53%) proceeded to MUD transplantation. White patients and those with common haplotypes were more likely to have a MUD identified (odds ratio [OR], 7.4 [P < .0001]; OR, 41.6 [P < .0001]), and were more likely to proceed to transplantation with a MUD (OR, 11.2 [P < .0001]; OR, 85.1 [P = .002]). In addition, patients who were newly diagnosed/in remission at the time of MUD search had a higher probability of receiving a transplant (OR, 2.01 [P = .013]) and better progression-free survival (PFS; P < .0001). In multivariate analysis for patients who received a transplant, donor type did not influence PFS at 3 years, which was 40% for MUD and 57% for haploidentical transplants, respectively (hazard ratio, 1.2 [P = .50]). In conclusion, race, haplotype frequency, and disease status at the time of MUD search influence the probability of identifying a MUD and receiving a transplant. Patients with a low likelihood of receiving a MUD transplant may proceed to a haploidentical transplant as soon as indicated, as this approach does not appear to compromise transplant outcomes.

[1]  M. Solh,et al.  Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  B. Sandmaier,et al.  Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B‐Cell acute lymphoblastic leukemia , 2017, Cancer.

[3]  J. Esteve,et al.  Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT , 2017, Journal of Hematology & Oncology.

[4]  S. Montoto,et al.  Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report , 2017, Bone Marrow Transplantation.

[5]  S. Davies,et al.  How Long Does it Take to Find a Matched Unrelated Donor in 2016 , 2017 .

[6]  Hongkun Wang,et al.  Comparative Outcomes after Haploidentical or Unrelated Donor Bone Marrow or Blood Stem Cell Transplantation in Adult Patients with Hematological Malignancies. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  A. Gennery,et al.  Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually , 2016, Bone Marrow Transplantation.

[8]  Y. Kodera,et al.  Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey , 2016, Bone Marrow Transplantation.

[9]  Sonali M. Smith,et al.  Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. , 2016, Blood.

[10]  R. Bouabdallah,et al.  Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  R. Vij,et al.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. , 2015, Blood.

[12]  Karl Frauendorfer,et al.  One million haemopoietic stem-cell transplants: a retrospective observational study. , 2015, The Lancet. Haematology.

[13]  M. Konopleva,et al.  Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  M. Gobbi,et al.  Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  Loren Gragert,et al.  HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.

[16]  M. Schell,et al.  Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization , 2013, Bone Marrow Transplantation.

[17]  S. Solomon,et al.  T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Tao Wang,et al.  Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. , 2012, Blood.

[19]  M. Horowitz,et al.  Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. , 2012, Blood.

[20]  R. Champlin,et al.  Progress in haploidentical stem cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  Y. Kodera,et al.  Worldwide network for blood and marrow transplantation , 2009 .

[22]  M. Maris,et al.  Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  K. Ballen,et al.  The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  S. Spellman,et al.  National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  F. Appelbaum Allogeneic hematopoietic cell transplantation for acute myeloid leukemia when a matched related donor is not available. , 2008, Hematology. American Society of Hematology. Education Program.

[26]  Harriet Noreen,et al.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. , 2007, Blood.

[27]  Edward A Copelan,et al.  Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.

[28]  Harriet Noreen,et al.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. , 2004, Blood.

[29]  A. Hagenbeek,et al.  Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukaemia , 2002, Bone Marrow Transplantation.